Palatin Technologies (NASDAQ:PTN) Announces Earnings Results

Palatin Technologies (NASDAQ:PTN – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($1.29) earnings per share for the quarter, FiscalAI reports. Palatin Technologies had a negative return on equity of 115.00% and a negative net margin of 63.54%. The business had revenue of $0.36 million for the quarter.

Palatin Technologies Trading Down 11.9%

NASDAQ:PTN traded down $0.73 during mid-day trading on Wednesday, hitting $5.40. 2,404 shares of the stock were exchanged, compared to its average volume of 35,510. The stock has a market cap of $9.61 million, a P/E ratio of -67.50 and a beta of 0.75. Palatin Technologies has a fifty-two week low of $4.51 and a fifty-two week high of $31.00.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. HC Wainwright assumed coverage on Palatin Technologies in a report on Friday, November 6th. They set a “buy” rating and a $12.00 target price on the stock. Weiss Ratings assumed coverage on shares of Palatin Technologies in a research report on Wednesday, November 4th. They set a “sell (e+)” rating for the company. Finally, Zacks Research initiated coverage on shares of Palatin Technologies in a report on Friday, November 6th. They issued a “hold” rating on the stock. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Palatin Technologies has an average rating of “Hold” and an average price target of $12.00.

Check Out Our Latest Analysis on PTN

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Palatin Technologies stock. State Street Corp acquired a new position in shares of Palatin Technologies (NASDAQ:PTN – Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 14,000 shares of the company’s stock, valued at approximately $124,000. State Street Corp owned 0.79% of Palatin Technologies at the end of the most recent reporting period. 11.50% of the stock is owned by institutional investors and hedge funds.

Palatin Technologies Company Profile

(Get Free Report)

Palatin Technologies is a biopharmaceutical company that develops peptide-based medicines designed to act on specific receptors. Its research has focused primarily on the melanocortin system, which is involved in a range of biological functions and potential therapeutic applications. The company’s commercial product is Vyleesi (bremelanotide), an injectable prescription medicine approved in the United States to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women.

Read More

Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.